SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ — Hublot proudly welcomes Jung Kook, global artist, performer, and member of 21st century pop icons, BTS, as its new Global Brand Ambassador. The announcement has been celebrated in Seoul, marking the fusion of two worlds that have redefined what it means to be original: a watchmaker that reshaped modern horology and an artist who reshaped the sound and rhythm of a generation. From the first fusion of gold and rubber in 1980, to the shockwave of the Big Bang in 2005 and now the reinvention of the Big Bang Original Unico, Hublot has turned innovation into identity. Jung Kook mirrors that same spirit: blending genres, creativity, emotions and instinct. The collaboration is not a coincidence; it is a convergence. Both the artist and Hublot go back to their origins, carrying with them the unmistakable DNA that makes them stand apart.

Hublot announces Jung Kook as new global Ambassador

On the partnership, Jung Kook stated: “Performing Dreamers at the FIFA World Cup in 2022, with Hublot as Official Timekeeper of the competition, was a moment where time and music felt connected. Now, collaborating with Hublot feels like that moment coming full circle. I’ve always admired the brand’s confidence, its craftsmanship, its way of creating its own path. 

Julien Tornare, Hublot CEO, affirmed: “Jung Kook is one of the most influential artists of his generation. His precision, his passion and his willingness to push boundaries reflect the very spirit of Hublot. Just as we continuously rethink, refine and re-engineer our creations, from the fusion of materials to the mastery of our in-house movements, Jung Kook carries the spirit of evolution, always transforming, always original. We are honored to welcome him into the Hublot family.”

BEYOND APPEARANCES: THE INNER ESSENCE WITHIN JUNG KOOK X HUBLOT 
Just as Hublot has evolved through innovation and reinvention, both are defined by depth and substance. In the same way, Hublot reveals its essence through mastery of its manufacture, the fusion of materials and technologies and the creation of its in-house Unico movement.

In 2005, Hublot did more than introduce a watch: it ignited a modern revolution. With the Big Bang, Hublot took fusion and turned it into modern alchemy, created a new visual language and established a design that that has marked two decades, defining Hublot’s legacy and continuing to shape what’s next. Since 2013, the year of his debut on stage, Jung Kook has blended genres, creativity and emotions, shaping a voice unmistakably his own. Today, with the 2026 announcement of Jung Kook as Global Brand Ambassador, Hublot celebrates the meeting of an artist who redefines originality and a watch that has just returned to its own beginnings with the Big Bang Original Unico.

WHY THE BIG BANG ORIGINAL UNICO BELONGS ON JUNG KOOK‘S WRIST
The Big Bang Original Unico, launched in January 2026, carries twenty years of Hublot mastery, from the very first fusion in 1980, to the design revolution of 2005, to its reinvention in 2026. It is built layer by layer, just as the artist builds himself song by song. Jung Kook’s career reflects a journey defined by ongoing growth and artistic exploration. His work continues to evolve in ways that build on past achievements while opening new creative possibilities. In this context, the Big Bang Original Unico serves as a meaningful partner that aligns with his individual style and artistic direction—rather than a symbol of any singular narrative. This is why the Big Bang Original Unico is not just a timepiece on his wrist. It is an extension of his creative code.

HUBLOT

In 1980 and for the first time, a watch dared to put a gold case on a rubber strap, turning the luxury watch world upside down in the process. Named for the porthole-shaped bezel with its exposed screws, Hublot was born and with it, the Art of Fusion.

In 2005 the brand took this exercise in creative thinking to a new level with the Big Bang and its iconic design, size and layered construction case. That same year, Hublot received the Best Design award at the Grand Prix d’Horlogerie de Genève. Since then, spurred by this revolutionary mindset, the Big Bang has never stopped reinventing itself. The twenty-first century has its first watch Icon.

The concept of fusion is omnipresent, the guiding principle for every collection. Big Bang timepieces reshape the geometries of time; Classic Fusion balances boldness and restraint, while the Exceptional Timepieces overwrite expectations to create unprecedented horological objects. With its disruptive approach of challenging convention, Hublot’s DNA is transcribed in the Unico, Meca-10 and tourbillon in-house movements, to add another tier of meaning to the Art of Fusion.

Alchemy is ingrained into Hublot and not just at La Manufacture. Magic can take place on a football pitch, producing partnerships with major events (UEFA Champions League and UEFA Euro™). Sometimes it happens at a concert, a basketball match, an artistic performance or at a unique gastronomic experience with Hublot’s family of starred Chefs. And so, the Hublot Vibes come to life, through shared moments of exaltation amongst the Hublotistas, its very own community of proud Hublot owners. The Art of Fusion goes beyond the tangible. It is a way of being, the Hublot way of life.

THE UNIQUENESS OF THE HUBLOT UNICO IN-HOUSE MOVEMENT

Born in 2010, the Unico was the first movement entirely designed, developed and manufactured in-house by Hublot, marking a new era of independence, innovation and identity for the brand. Over the years, it has evolved into a bold and unmistakable signature of Hublot watchmaking, known for its robust and revolutionary chronograph design.

With standout features like a front-facing column wheel, silicon escapement, the Unico movement is a mechanical force that’s as visually striking as it is technically advanced. It’s not just what powers the watch, it’s what defines it.

Key features include an integrated flyback chronograph precise to 1/8th of a second for instant reset and restart, an accuracy of -2/+4 seconds per day, a 72-hour power reserve. The movement also holds five patented innovations, covering: dual oscillating clutches, an anti-trembling system, a “zero friction” ratchet wheel blocker, a fine balance wheel adjustment system and constant-pressure friction system for the minute counter all rigorously tested through Hublot’s Chronofiable® protocol to ensure optimal performance, reliability, and precision.

HUBLOT: www.hublot.com

ZUG, Switzerland, Feb. 12, 2026 /PRNewswire/ — Berlin Heals Holding AG, a MedTech company focused on transformative therapies for heart failure, today announced the successful closing of a new financing round, raising over 10M USD from a combination of existing shareholders and new investors. The funding will be used to advance the company’s cardiac microcurrent technology and expand its clinical research program.

Berlin Heals has developed a novel therapeutic approach for the treatment of heart failure based on its proprietary implantable device, C-MIC (Cardiac Microcurrent). The system has already demonstrated impressive clinical outcomes, but the company continues to expand on the evidence. Berlin Heals will be presenting updated clinical data at major cardiology conferences throughout this year, as well as publish new publications.

Berlin Heals is entering the next phase of innovation, focusing on less invasive implantation techniques and enhanced device designs intended to broaden patient eligibility and streamline future adoption. The newly secured capital will support expanding indications into wider patient populations and begin larger double blinded trials to prepare for the FDA IDE submission.

Berlin Heals has previously demonstrated sustained functional and quality-of-life improvements in patients with dilated cardiomyopathy treated with C-MIC. Long-term follow-up data from early studies continue to support the durability of the therapy, reinforcing confidence in the company’s clinical and regulatory strategy.

John Brumfield, Chief Executive Office of Berlin Heals Holding, added:

“Closing this financing round marks an important milestone for us. We are deeply thankful to our Co-Founder of Berlin Heals Holding Ltd. and the Member of the Board – Marko Bagaric for achieving another impressive round of financing. His long-term vision and dedication to this company is crucial for the trust of our long-standing shareholders and welcoming new investors who share our vision. Having this strong background and support, together with our clinical data, we now have even more confidence to move into less invasive solutions that could significantly expand the impact of our therapy. This funding allows us as well to take decisive steps toward global commercialization.”

Rob ten Hoedt, Board Chairman of Berlin Heals Holding AG, commented:

“Heart failure remains an area of tremendous unmet medical need. Having followed the growth of Berlin Heals, I am convinced that this technology has the potential to redefine how we treat heart failure patients. This financing enables the company to translate its innovation into a therapy that can reach many more patients worldwide and influence greatly their quality of life.”

Berlin Heals Holding AG is a Swiss joint-stock company founded in 2014. The company’s C-MIC technology delivers a constant electrical microcurrent to the heart, generating a localized electrical field designed to improve cardiac function. Based on clinical studies to date, this approach has shown the potential to deliver rapid and sustained benefits for patients suffering from heart failure.

The collaboration enhances MSIG’s platform-enabled model, leveraging Peak3’s intelligent core system to elevate ecosystem connectivity and multi-country growth.

SINGAPORE, Feb. 12, 2026 /PRNewswire/ — MSIG Asia today announced the appointment of Peak3 as its digital insurance platform partner, marking a strategic acceleration of the general insurer’s market leadership in digital insurance and reinforcing its position as the region’s partner of choice for intelligent, embedded protection.

MSIG, the largest non-life regional insurer in Southeast Asia based on gross written premiums, is already powering embedded insurance for some of the region’s largest platforms and ecosystems, helping to close the protection gap for millions of users today. Through this partnership, MSIG is extending its reach across Asia’s interconnected digital economies, deepening ecosystem connectivity and strengthening its ability to deliver flexible, needs-based insurance at scale, through both direct-to-consumer channels and strategic partnerships.

Graphene, Peak3’s intelligent insurance core system, brings proven experience supporting high-volume operations and diverse distribution models. It is designed for rapid product configuration, consistent multi-country execution, and operational efficiency at scale. This technology unlocks new pathways for MSIG to serve partners where digital experiences are being built, creating symbiotic partnerships with platforms, accelerating time-to-market through pre-connected distribution while creating shared, compounding value.

Building on Peak3’s digital- and AI-first insurance technology, MSIG delivers solutions designed for on-demand, contextual customer needs. This shifts protection from one-size-fits-all to moment-relevant coverage that adapts to real-world needs. Through modular coverage and seamless distribution, MSIG continues its evolution from product provider to platform-enabled risk partner, delivering scalable, profitable business models that support inclusive insurance across emerging digital economies.

For customers, this translates into protection that fits naturally into their everyday lives — relevant, timely coverage delivered where they already transact, creating more trusted, seamless experiences.

Clemens Philippi, Chief Executive Officer, MSIG Asia, said:

“This investment is directly related to and supports our MSIG Asia 2029 Growth Ambition. We’re backing our digital capabilities with the right talent and partnerships to compete and win, coupled with our unmatched footprint across Southeast Asia and our commitment to close the protection gap. This partnership strengthens our foundation and expands our reach across the region’s most important commercial ecosystems.”

Adrian Hill, Chief Digital & Consumer Officer, MSIG Asia, added:

“We’ve built MSIG into a digital insurance leader in Asia by creating symbiotic partnerships where platforms, consumers, and insurers advance together. Together with Peak3, we unlock new scale and speed – empowering us to serve more partners and bring intelligent nano insurance and on-demand protection to life across Asia’s largest digital ecosystems.”

Bill Song, Group CEO, Peak3, said:

“We’re proud to partner with MSIG as they expand across Asia, bringing together our intelligent and connected insurance core, Graphene, and MSIG’s strong regional presence. This collaboration supports our shared goal of accelerating multi-country growth, enabling new partnership models, and delivering consistent, high-quality insurance experiences at scale.”

By expanding ecosystem connectivity and embedding intelligence at the foundation in collaboration with Peak3, MSIG continues to set the benchmark for next-generation insurance infrastructure, enabling partners to grow faster and customers to be protected more meaningfully across Asia’s digital ecosystems.

About MSIG Asia

MSIG, one of Asia’s leading general insurance brands, is a member of the MS&AD Insurance Group Holdings Inc. and a wholly owned subsidiary of Mitsui Sumitomo Insurance Co. Ltd., boasting a robust credit rating of A+ Stable. With over 40,000 employees and presence in 48 countries and regions globally, the Group is amongst the world’s top non-life insurance groups based on gross revenue. Within Asia Pacific, MSIG has an extensive regional footprint across Southeast Asia and key markets including Australia, New Zealand, Hong Kong, China, Korea, India and Taiwan. It is the top non-life regional insurance provider in Southeast Asia based on gross written premiums.  MSIG’s network also includes MS First Capital, headquartered in Singapore, and the Asia Pacific operations of MS Amlin. MS First Capital specialises in Corporate, Marine Hull, and unconventional risks, while MS Amlin delivers specialised insurance solutions in Property & Casualty, Marine & Aviation, and Reinsurance sectors.
www.msig-asia.com

About Peak3

Peak3 is a global provider of digital and AI-driven software solutions for the insurance industry. Specialising in cloud-native core and orchestration platforms and innovative data and AI applications, Peak3 enables insurers, MGAs, and intermediaries across life, health, and P&C insurance to accelerate growth, enhance customer experience, and improve operational efficiency. Headquartered in Singapore, Peak3 serves over 50 clients in more than 20 countries across EMEA and APAC.
www.peak3.com

SINGAPORE, Feb. 12, 2026 /PRNewswire/ — Philips Monitors today unveils the Evnia 27M2N6501L, a premium QD-OLED gaming monitor engineered to deliver breathtaking immersion and seamless performance. In partnership with Yakuza Kiwami 3 Dark Ties, they aim to deliver an unprecedented immersive gaming experience. Combining cutting-edge QD-OLED panel technology, a 240Hz refresh rate, and AI-enhanced lighting, the monitor makes premium visual performance accessible to more gamers at an attractive price.

Elevating Game Worlds with Visual Intelligence
The collaboration will fully leverage the 27M2N6501L’s strengths in image quality, smoothness, and color performance, offering players of Yakuza Kiwami 3 Dark Ties a more realistic, fluid, and visually stunning experience. Whether it’s the neon-lit streets in the Yakuza Kiwami 3 campaignYAKUZA KIWAMI 3″ or the shadow-rich environments of  Dark Ties, the QD-OLED technology delivers extreme contrast, deep blacks, and vibrant colors, pulling players deeper into the game world with every detail.

Engineered for Elite Performance

• True QD-OLED Display: Self-lit pixels with Quantum Dot color for infinite contrast, rich blacks, and ultra-wide viewing angles
• QHD 2560×1440 Resolution: Sharper imagery, clearer targets, enhanced spatial awareness
• 240Hz Refresh Rate & G-Sync Compatible Support: Tear-free, blur-free motion for split-second reactions
• AI-Powered smartImage game mode: Optimized for gamers, Stark ShadowBoot and Smart Crosshair, for better aim, visibility in dark scenes, and more fun.
• DisplayPort 1.4: Instant compatibility with next-gen consoles and high-performance PCs
• Game-Enhancing Suite: Smart Crosshair, Shadow Boost, and Smart Sniper modes for tactical advantage

“Gaming is about feeling the action, not just seeing it, ” said Hawk Chang, Product director of APAC.  “With the Evnia 27M2N6501L and our partners at SEGA, we’re delivering a display that connects players to the game on a sensory level—where speed, clarity, and immersion come together seamlessly.”

Built for Long Sessions & Lasting Comfort
Designed with well-being in mind, the monitor includes Flicker-Free technology, Low Blue Light mode, and a fully adjustable stand. MultiView allows simultaneous multi-device screen sharing, while a long warranty with OLED burn-in coverage ensures confidence in every purchase.

About Philips Evnia
Evnia is Philips high-performance monitor brand dedicated to gaming, committed to bringing leading display technologies to a wider audience at an accessible price and advancing the immersive gaming experience.

SANTA CLARA, Calif., Feb. 12, 2026 /PRNewswire/ — The article is from Shuzhi Society.

On February 8th, U.S. local time, Dreame Robot Laundry made a landmark appearance in a coveted prime-time advertising slot during the 60th Super Bowl. Its 30-second commercial, airing on the event’s exclusive broadcaster, NBC, presented the brand’s high-end laundry solutions to millions of American households.

This strategic investment transcends traditional media exposure, representing a calculated move in premium brand positioning. As the most-watched television event in the United States, the Super Bowl serves not only as a cultural phenomenon but also as a globally recognized platform for establishing brand credibility and prestige. Dreame’s successful placement during this premier broadcast underscores its serious commitment to the North American market, a commitment further validated by the brand’s remarkable 189% year-over-year revenue growth in the region during 2025, demonstrating strong market traction and consumer acceptance.

The commercial prominently featured Dreame’s flagship L9 Washer-Dryer Set, highlighting its advanced capabilities in intelligent fabric sensing, specialized care programs, and cutting-edge washing technology. This focused presentation aligns perfectly with the brand’s strategic identity as a “technology-driven provider of premium home laundry solutions” – a carefully crafted message designed to resonate with the values and expectations of discerning American consumers who prioritize innovation, efficiency, and superior results in home appliances.

This Super Bowl debut marks a pivotal chapter in Dreame’s ambitious global expansion within the high-end smart home ecosystem. Since its founding in 2017, the company has executed a rapid and successful international growth strategy, establishing a commercial presence in over 120 countries and regions worldwide. The laundry category serves as a cornerstone of home appliances, supported by a robust intellectual property portfolio of over 210 patents and manufactured at a state-of-the-art, fully automated smart factory with an annual production capacity exceeding 2.5 million units, ensuring consistent quality and scalability.

Beyond immediate brand exposure, this Super Bowl initiative solidifies Dreame’s position as a forward-thinking global innovator in intelligent home care. It provides an unparalleled platform to engage directly with the core U.S. consumer base, building brand familiarity and trust that paves the way for sustained market penetration, future product introductions, and long-term category leadership. Furthermore, Dreame’s strategic approach offers an insightful and practical case study for other consumer technology and home appliance brands from China and beyond, demonstrating a viable pathway to building relevance and competitiveness in mature, high-stakes international markets like North America.

SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ — J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading oncology journal published by the American Association for Cancer Research (AACR). According to the most recent Journal Citation Reports (2025), the journal has an Impact Factor of 10.2, reflecting its influence in translational and clinical cancer research.

The study presents a therapeutic strategy designed to overcome EGFR C797S, a major resistance mutation that commonly emerges following treatment with the third-generation EGFR inhibitor Tagrisso. By integrating comprehensive preclinical findings with early clinical observations, the research outlines a potential new treatment approach for patients with EGFR-mutant non–small cell lung cancer (NSCLC) who have limited options after Tagrisso failure.

EGFR-mutant NSCLC is driven by aberrant activation of EGFR signaling, and while EGFR-targeted therapies have dramatically improved outcomes over the past decade, acquired resistance remains inevitable for most, if not all patients. In particular, the C797S mutation is known as a representative resistance mechanism that emerges, preventing existing third-generation EGFR targeted therapies from working effectively. Currently, there are no approved treatments targeting the C797S mutation. JIN-A02 was developed as an orally available, fourth-generation EGFR inhibitor engineered to selectively target resistance-associated EGFR mutations, including C797S and T790M, while minimizing activity against wild-type EGFR. In preclinical models derived from patients with EGFR E19del/T790M/C797S mutant NSCLC that are resistant to Tagrisso, JIN-A02 demonstrated marked antitumor activity, achieving a maximum tumor growth inhibition (TGI) of 168.2%, substantially exceeding the effects observed with Tagrisso under the same conditions and indicating tumor regression. This means that it was observed that administration of JIN-A02 could reduce tumor size beyond simple growth inhibition.

Tumor tissue analyses showed significant reductions in phosphorylated EGFR (p-EGFR) and the proliferation marker Ki-67 following JIN-A02 treatment, confirming effective inhibition of EGFR-driven signaling at the molecular level. In intracranial tumor models reflecting brain metastases, JIN-A02 produced rapid and sustained reductions in tumor burden, suggesting the ability to achieve therapeutically meaningful exposure across the blood–brain barrier (BBB).

The publication also reports early clinical observations from an ongoing Phase 1/2 trial (NCT05394831) in patients with EGFR-mutant NSCLC who progressed after prior EGFR-targeted therapies and chemotherapy. As of the data cutoff, 23 patients had been treated with JIN-A02, with partial responses and stable disease observed in multiple cases. Notably, one patient in the 300 mg dose cohort achieved a partial response, with a 39.7% reduction in lung lesion size observed at the start of the third treatment cycle. This response was sustained through the seventh cycle, reaching a maximum reduction of 44.9%. In addition, the patient’s brain metastatic lesions decreased by 25% at the fifth treatment cycle, with the response maintained throughout the seventh cycle.

In addition, blood-based circulating tumor DNA (ctDNA) analysis in this patient showed complete clearance of the EGFR C797S mutation and the exon 19 deletion, along with a reduction of more than 90% in the T790M mutation. These findings are interpreted as evidence that the molecular-level target inhibition achieved by JIN-A02 translated into a meaningful clinical response.

Professor Sun Min Lim of the Division of Medical Oncology at Severance Hospital, the corresponding author of the study, stated, “JIN-A02 has demonstrated meaningful preclinical activity and early clinical signals targeting C797S-mediated resistance, for which treatment options have been extremely limited following the failure of third-generation EGFR-targeted therapies. In particular, the observed activity in brain metastases, along with a reduction in EGFR mutations detected in plasma ctDNA, provides important support for its further clinical development.”

J INTS BIO plans to further accelerate the clinical development of JIN-A02, focusing on dose optimization, expansion of clinical data in patients with brain metastases, and further validation of molecular response biomarkers, with the goal of establishing a new treatment option for patients with EGFR-mutant NSCLC who have exhausted current standard therapies.